Livforsakringsbolaget Skandia Omsesidigt Has $18.32 Million Stock Position in United Therapeutics Corporation $UTHR

Livforsakringsbolaget Skandia Omsesidigt increased its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 45.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 30,900 shares of the biotechnology company’s stock after buying an additional 9,700 shares during the period. Livforsakringsbolaget Skandia Omsesidigt’s holdings in United Therapeutics were worth $18,316,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of UTHR. Emerald Mutual Fund Advisers Trust raised its holdings in United Therapeutics by 10.3% in the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 8,384 shares of the biotechnology company’s stock worth $4,972,000 after acquiring an additional 784 shares during the period. Bryn Mawr Trust Advisors LLC boosted its holdings in United Therapeutics by 5.4% during the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after acquiring an additional 24 shares during the period. Archer Investment Corp boosted its holdings in United Therapeutics by 23.9% during the first quarter. Archer Investment Corp now owns 519 shares of the biotechnology company’s stock valued at $308,000 after acquiring an additional 100 shares during the period. State of Michigan Retirement System grew its position in shares of United Therapeutics by 1.7% in the first quarter. State of Michigan Retirement System now owns 11,732 shares of the biotechnology company’s stock valued at $6,957,000 after purchasing an additional 200 shares during the last quarter. Finally, Principal Financial Group Inc. grew its position in shares of United Therapeutics by 3.6% in the first quarter. Principal Financial Group Inc. now owns 101,692 shares of the biotechnology company’s stock valued at $60,301,000 after purchasing an additional 3,534 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $577.18, for a total transaction of $5,771,800.00. Following the sale, the chief financial officer owned 18,876 shares in the company, valued at $10,894,849.68. The trade was a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold 593,543 shares of company stock valued at $333,134,813 over the last three months. 8.60% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts recently weighed in on UTHR shares. Bank of America cut their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Raymond James Financial started coverage on United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price on the stock. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. HC Wainwright upped their price target on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Finally, Morgan Stanley set a $516.00 price objective on United Therapeutics in a research report on Thursday, May 7th. Ten equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $644.82.

United Therapeutics Stock Down 1.7%

United Therapeutics stock opened at $526.66 on Wednesday. The business has a 50 day moving average price of $555.07 and a two-hundred day moving average price of $529.82. The stock has a market cap of $22.36 billion, a price-to-earnings ratio of 19.44, a price-to-earnings-growth ratio of 1.79 and a beta of 0.58. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period in the previous year, the business posted $6.63 EPS. On average, analysts expect that United Therapeutics Corporation will post 26.63 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.